Suchergebnisse - "Shimokawa, Mototsugu"

PubPharm (556)

1

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer : A phase II trial (HYBRID)

enthalten in: Cancer medicine | 2024

von Arai, H. | Tsuda, T. | Sunakawa, Y. | +13

2

IDENTIFICATION OF MUC1-C AS A TARGET FOR SUPPRESSING PROGRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS

enthalten in: Cancer research communications | 2024

von Nakashoji, A. | Haratake, N. | Bhattacharya, A. | +15

3

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservational study (NAPOLEON-2)

enthalten in: ResearchSquare.com | 2024

von Kodama, T. | Imajima, T. | Shimokawa, M. | +32

4

Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan : The CReGYT-01 EGFR study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Katsumata, S. | Shimokawa, M. | Hamada, A. | +40

5

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Haratake, N. | Ozawa, H. | Morimoto, Y. | +16

6

Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2)

enthalten in: Annals of gastroenterological surgery | 2024

von Miyashita, Y. | Oki, E. | Kamori, T. | +7

7

Author Correction : C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

enthalten in: Scientific reports | 2024

von Shirakawa, T. | Makiyama, A. | Shimokawa, M. | +19

ErratumFor: Sci Rep. 2023 May 31;13(1):8815. - PMID 37258608

8

Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma : Analysis of US national registry data

enthalten in: Hepatology research : the official journal of the Japan Society of Hepatology | 2024

von Bekki, Y. | Itoh, S. | Toshima, T. | +2

9

Treatment-related adverse events of combination chemoimmunotherapy versus chemotherapy alone in first-line treatment for non-small cell lung cancer : a systematic review and meta-analysis of randomized clinical trials

enthalten in: Journal of thoracic disease | 2024

von Takada, K. | Takamori, S. | Mizuki, F. | +3

10

Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer : RELIANCE Trial

enthalten in: Clinical lung cancer | 2024

von Matsubara, T. | Yamaguchi, M. | Shimokawa, M. | +1

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[56]